Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: ENO2 drives tumor cell-induced M2 macrophage polarization to promote colorectal cancer liver metastasis

Fig. 3The alternative text for this image may have been generated using AI.

ENO2 Drives Metastatic Progression and Serves as a Therapeutic Target. a Ten candidate genes were screened from the ‘Module 11’ gene set and ‘Cancer cell 3’ characteristic genes. b Correlation analysis of 10 candidate genes and prognosis of colorectal cancer based on multivariate Cox regression in the TCGA-COAD database. c Detection of the correlation between ENO2 expression and colorectal cancer progression using immunohistochemistry in multiple independent cohorts. d Using three independent sample cohorts from Nanjing and Guangzhou, Kaplan-Meier analysis was conducted to investigate the association between ENO2 expression and the prognosis of colorectal cancer. e Observation of the tumorigenic ability of ENO2 knockout DLD-1 cells in a C57BL/6 J mouse subcutaneous tumor model and comparison of the weight and volume of the tumor tissues. f Using the intrasplenic injection model in C57BL/6 J mice, we observed the number of liver metastatic nodules formed by ENO2-KO DLD-1 cells compared with wild-type cells. g Using pharmacological inhibition of ENO2 (ENOblock) to validate the potential of targeting ENO2 to inhibit CRLM. h Multiplex immunofluorescence of EMT markers (E-cadherin, vimentin) in control and ENO2-modulated cancer cells

Back to article page